Phosphonylmethoxyalkylpurines and pyrimidines exhibit potent activity
against a broad spectrum of DNA viruses. We evaluated some of these nu
cleotide analogues for antitrypanosomal activity in vitro and in mice.
The most active compounds were (S)-9-(3-hydroxy-2-phosphonylmethoxypr
opyl) adenine (HPMPA) and droxy-2-phosphonylmethoxypropyl)-2,6-diamino
purine (HPMPDAP), which inhibited growth of Trypanosoma brucei brucei
by 50% (EC(50) value) when incubated in vitro for 24 hr with 0.23-5.69
mu g drug/ml. Both compounds completely eliminated multidrug-resistan
t T. b. brucei in culture at 1 mu g/ml after 4-5 days exposure. Mice i
nfected with drug-susceptible T. b. brucei were cured with 2 doses of
10 mg/kg HPMPDAP. Two or 5 doses of 50 mg/kg 9-(2-phosphonylmethoxyeth
yl) adenine (PMEA) or 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (
PMEDAP), respectively, were necessary to eliminate T. b. brucei infect
ions in mice. Mice infected with multidrug-resistant T. b. brucei were
not cured with the above dosages. The most active compound against Tr
ypanosoma congolense was PMEDAP with an EC(50) value of 3.21-11.63 mu
g/ml. Thus, some of the phosphonylmethoxyalkyl purines showed potentia
l as antitrypanosomal compounds at dosages that are below those toxic
for mice.